Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Mylan Inc.

Home Clinical Trial Sponsors and OrganizationsMylan Inc.

Mylan Inc.

1000 Mylan Blvd, Canonsburg, Pennsylvania, United Stateswww.mylan.com35,000 employeesEstablished: 1961-01-01

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

54

4 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

1961

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 3

21

38.9%

Phase 1

12

22.2%

Phase 2

6

11.1%

Not Applicable

2

3.7%

Phase 4

2

3.7%

Trial Status Distribution

Active, not recruiting

4

7.4%

Completed

46

85.2%

Recruiting

2

3.7%

Terminated

2

3.7%

Clinical Trials

Trials sponsored by this organization (54)

Study to Evaluate the Effectiveness of Legalon®

Aug 2022362 participants

Observational Study to Evaluate the Actual Use and Effectiveness of Dymista® Nasal Spray in Asian Patients

Oct 2021924 participants

Abacavir, Dolutegravir and Lamivudine Dispersible Tablets (60 mg/5 mg/30 mg)

Aug 202143 participants

Observational Study to Evaluate the Actual Use of Elidel® in Chinese Patients With Mild to Moderate Atopic Dermatitis

Mar 2021130 participants

Observation of the Effects of Guideline-driven Lifestyle Interventions, Including Use of a Red-yeast Based Nutraceutical

Dec 2020259 participants

Dose-Response Study of MR-107A-01 in The Treatment of Post-Surgical Dental Pain

Sep 2020114 participants

An extension clinical trial to study the effects of investigational medicine MYL-1701P in patients with Diabetic Macular Edema

Mar 202070 participants

Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and EyleaÂ® in Subjects With Diabetic Macular Edema

Sep 2019356 participants

Page 1 of 7

Approvals

No approval data available

News

Biocon's Pegfilgrastim Biosimilar Wins Japanese Approval, Expanding Biosimilar Footprint

- Biocon has received marketing approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for its pegfilgrastim biosimilar, confirmed on August 25, 2026. - The product, developed and manufactured by wholly-owned subsidiary Biocon Biologics Ltd., serves as a biosimilar to Neulasta®, a registered trademark of Amgen Inc. - Sandoz K.K. will exclusively promote, sell, and distribute the pegfilgrastim biosimilar in Japan, with Global Regulatory Partners Japan acting as Marketing Authorization Holder. - The approval strengthens Biocon's biosimilar portfolio in one of Asia's largest pharmaceutical markets and reaffirms its commitment to increasing patient access to affordable medications.

On this page

Overview
Clinical Trials54
Approvals
News1

Back to Organizations